Appropriate prescribing of Oxycodone for non-cancer pain in general practice

Similar documents
Reviewing patients using opioid medicines long-term for non-cancer pain

Improving safety for patients taking an ACE inhibitor/arb + diuretic

Lowering serum urate levels in patients with gout

Reviewing the long-term use of selective serotonin reuptake inhibitors in patients with depression

Identifying patients who may benefit from stepping down PPI treatment

Optimising asthma management in high risk patients

CLINICAL AUDIT. The safe and effective use of. Methotrexate

Monitoring polypharmacy and reducing problematic prescribing

CLINICAL AUDIT. Renal Function Testing in People. Taking Dabigatran

CLINICAL AUDIT. Safe and Effective. Anticoagulation. with Warfarin

CLINICAL AUDIT. Laboratory Investigation of. UTI in Primary Care

CLINICAL AUDIT. Laboratory Testing in. Diabetes. in Primary Care

Asthma: Bronchodilator Overuse Review (MOPS Accredited until August 2020)

CLINICAL AUDIT. Initiating Insulin. in Patients with Type 2 Diabetes

Sore throat management of at-risk people

Safe use of Lithium therapy

Monitoring of Thyroid Replacement Therapy

The Laboratory Investigation of. Tiredness. Clinical Audit. better medicin

Application for Endorsement of CQI (Clinical Audit) Activities for MOPS Credits Allocation

Update on OXYCODONE. what can primary care do about the problem? 8 BPJ Issue 44

Dr Alistair Dunn. General Practitioner Northland District Health Board Whangarei

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

Application for Endorsement of CQI (Clinical Audit) Activities for MOPS Credits Allocation

BACKGROUND Measuring renal function :

Oxycodone. Dr Alistair Dunn Addiction Medicine Specialist & General Practitioner

Oxycodone use still increasing

Berkshire West Area Prescribing Committee Guidance

Prescribing drugs of dependence in general practice, Part C

Rule Governing the Prescribing of Opioids for Pain

OPIOIDS FOR PERSISTENT PAIN: INFORMATION FOR PATIENTS

See Important Reminder at the end of this policy for important regulatory and legal information.

Switching Tramacet to paracetamol alone or paracetamol and codeine

See Important Reminder at the end of this policy for important regulatory and legal information.

Conversion chart from fentanyl to opana er

Guidelines for the Management of Chronic Non-Malignant Pain (CNMP) in Primary Care (not including neuropathic pain (NeP).

GG&C Chronic Non Malignant Pain Opioid Prescribing Guideline

Opioid Tapering and Withdrawal Guidance

GUIDELINES ON THE MANAGEMENT OF PAIN DUE TO CANCER IN ADULTS

RECERTIFICATION PROGRAMME FOR CONTINUING PROFESSIONAL DEVELOPMENT OF OPTOMETRISTS

CDC Guideline for Prescribing Opioids for Chronic Pain. Centers for Disease Control and Prevention National Center for Injury Prevention and Control

Persistent Pain Resources. Educational Slide Set

Coversheet for Network Site Specific Group Agreed Documentation

The fear of enabling. How to distinguish MISUSE OF PRESCRIPTION OPIOIDS: Steve s story a true account of prescription medicine misuse

Opioid epidemic and PEHP

NBPDP Drug Utilization Review Process Update

Dr Alistair Dunn. Lead Clinician Northland Health Community Mental Health & Addictions Northland DHB Whangarei

Opioid Management of Chronic (Non- Cancer) Pain

Analgesics: Management of Pain In the Elderly Handout Package

Demerol 50 mg vs hydrocodone

CLINICAL POLICY DEPARTMENT: Medical

Clinical Policy: Opioid Analgesics Reference Number: CP.PMN.97 Effective Date: Last Review Date: 02.18

Long Term Care Formulary HCD - 08

Opioid Induced Hyperalgesia (OIH)

Patient Information Leaflet. Opioid leaflet. Produced By: Chronic Pain Service

HOPE. Considerations. Considerations ISING. Safe Opioid Prescribing Guidelines for ACUTE Non-Malignant Pain

Medicare Part D Opioid Policies for 2019 Information for Patients

CDC Guideline for Prescribing Opioids for Chronic Pain

Dose equivalent of fentanyl patch to oxycontin

Opioid rotation or switching may be considered if a patient obtains pain relief with one opioid and is suffering severe adverse effects.

OAA Survey 156: Current prescribing practices for post-operative analgesia following emergency and elective LSCS

GUIDELINES AND AUDIT IMPLEMENTATION NETWORK

Atlas of Healthcare Variation

Opioid Management Change Package 2017/2018

Drug Name (specify drug) Quantity Frequency Strength

Proposed Changes to Existing Measure for HEDIS : Use of Opioids at High Dosage (UOD)

Top 10 narcotic pain pills

Drug Name (specify drug) Quantity Frequency Strength

STARSHIP WITHDRAWAL OF ANALGESIA AND SEDATION

Safe Prescribing of Drugs with Potential for Misuse/Diversion

New Guidelines for Prescribing Opioids for Chronic Pain

bpac nz better medicine Palliative Care Quiz Feedback

RECERTIFICATION PROGRAMME FOR CONTINUING PROFESSIONAL DEVELOPMENT OF OPTOMETRISTS

Supportive Care. End of Life Phase

Opioid Analgesics. Recommended starting dose for opioid-naïve patients

Clinical Policy: Opioid Analgesics Reference Number: CP.PMN.97 Effective Date: Last Review Date: 02.19

California. Prescribing and Dispensing Profile. Research current through November 2015.

Which is stronger 100 mg. tramadol or 5 mg oxycodone

Primary care review of Tramadol Prescribing

High Risk Medicines Prescribing Policy. July 2017

Opioids in the Community: Chronic pain, Palliative Care, and Addiction. Dr Ahmed Jakda September 2017

Policy on Pharmacological Therapies Practice Guidance Note Reducing Dosing Errors with Opioid Medicines V04

Prior Authorization for Opioid Products Indicated for Pain Management

B. Long-acting/Extended-release Opioids

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process High Priority

Pinni Meedha Mojutho Ammanu Dengina Koduku Part 1 Kama Kathalu

Mid Essex Locality Guideline for Management of Adult Acute and Chronic Non-Cancer Pain in Primary care

Pharmacogenetics of Codeine. Lily Mulugeta, Pharm.D Office of Clinical Pharmacology Pediatric Group FDA

Renal Palliative Care Last Days of Life

Q&A: Opioid Prescribing for Chronic Non-Malignant Pain

Re: Non-prescription availability of low-dose codeine products

Managing your pain

Breast screening. achieving equity. Key concepts: keyword: breastscreening

PAIN RELIEF AFTER SURGERY

Knock Out Opioid Abuse in New Jersey:

Medicines Optimisation Strategy

PRESCRIPTION DRUG MONITORING PROGRAM

Controlled Drug Process. Khoa Vo Masters candidate University of Canterbury

Mitigating Risks While Optimizing the Benefits of Pharmacologic Agents to Manage Pain in the Elderly

Allergic to hydrocodone can i take tramadol

DURATION LIMIT WITH QUANTITY LIMIT AND POST LIMIT PRIOR AUTHORIZATION CRITERIA IMMEDIATE-RELEASE OPIOID ANALGESICS (BRAND AND GENERIC)*

Transcription:

CLINICAL AUDIT Appropriate prescribing of Oxycodone for non-cancer pain in general practice Valid to October 2022 bpac nz better medicin e

Background Oxycodone is a strong opioid that milligram for milligram is approximately twice as potent as morphine. It is indicated for the treatment of moderate to severe pain, when morphine is not tolerated, and all other options have been considered. The majority of people dispensed oxycodone in New Zealand are initiated on this medicine outside of general practice, i.e. by a doctor in secondary care, however, general practitioners continue to initiate almost one-quarter * of prescriptions and continue oxycodone in 17% of people initiated in secondary care. 1 Clinicians are urged to assess whether the initiation or continuation of oxycodone is appropriate for each specific clinical situation, before writing a prescription. Morphine is the preferred first-line option for the treatment of acute and chronic moderate to severe pain, when a strong opioid is indicated. When compared to morphine, oxycodone: Has no better analgesic efficacy Has a similar adverse effect profile May have more addictive potential Is significantly more expensive Fentanyl or methadone are safer options in patients with renal impairment, who require a strong opioid, because they have no clinically significant active metabolites (unlike morphine and, to a lesser extent, oxycodone). In many cases, however, morphine can still be safely used in patients with renal impairment, if it is dosed carefully. Discussion with a renal physician is recommended in patients with a creatinine clearance < 30 ml/min. Remember that: 5 mg oxycodone is approximately equivalent to 10 mg morphine, 50 100 mg tramadol, 100mg dihydrocodeine or 100 mg codeine. Audit plan This audit aims to help you identify patients who have been dispensed oxycodone and then to consider whether or not this was the most appropriate analgesic medicine. The recommended steps for completing the audit are: 1. Identify all patients currently prescribed oxycodone 2. Assess whether they meet the indications for oxycodone treatment (below) 3. Where appropriate, switch the patient to another treatment or taper their dose Indications Although there are exceptions to every rule, in the majority of cases, oxycodone should only be prescribed if the patient: Is intolerant or allergic to morphine and; Has moderate to severe pain and; There has been an adequate trial of other treatments which have failed to control the pain In most cases, oxycodone should be a short-term treatment only and analgesia should be tapered as pain levels decrease. The dose of oxycodone can be stopped or slowly reduced and, where required, the patient can be switched to a weaker opioid and/or paracetamol. For further information, see Oxycodone: how did we get here and how do we fix it?, BPJ 62 (July, 2014): www.bpac. org.nz/bpj/2014/july/oxycodone.aspx Recommendations Oxycodone should only be prescribed for the treatment of moderate to severe pain in patients who are intolerant to morphine and when a strong opioid is the best option. When considering initiation of oxycodone, always ask yourself if you would use morphine for this patient. If the answer is no then do not prescribe oxycodone. Oxycodone should not be prescribed when a weaker opioid, e.g. codeine, dihydrocodeine or tramadol, would be more appropriate. 1. Ministry of Health. Pharmaceutical collection (national dispensing data), 2017. * This figure is gradually reducing from 32% in 2012 to 24% in 2017 N.B. Tapering or ceasing analgesia is unlikely to be appropriate for patients with cancer pain (or other palliative care conditions requiring ongoing pain relief), therefore this audit is restricted to patients using oxycodone for non-cancer /nonpalliative care pain. Criteria for a positive result Any patient currently being treated with oxycodone should have the following recorded in their notes: The indication for treatment with a strong opioid (exclude those being treated for cancer pain) The reason why morphine was not an appropriate treatment The recommended plan for reducing the dose, ceasing treatment and/or switching to another analgesic as required 2 Appropriate prescribing of oxycodone for non-cancer pain Clinical Audit www.bpac.org.nz/audits

And if the patient does not meet the required indications A note to recall the patient, to assess pain, and to taper the dose or switch to another analgesic Audit standards By the second data cycle of this audit, 90% of the patients who have been prescribed oxycodone in the previous 12 months will meet the required indications (i.e. moderate to severe pain requiring a strong opioid and intolerance or allergy to morphine). Data Eligible people All patients who have received a prescription for oxycodone for non-cancer pain in the previous 12 months are eligible for this audit. Identifying patients You will need to have a system in place that allows you to identify eligible patients. Many practices will be able to identify patients by running a query through their practice management software. Once a patient has been identified, assess whether the indication for analgesia warrants treatment with a strong opioid and if there is a record of an intolerance or allergy to morphine. Check whether there has been a recent assessment of the severity of the patient s pain and a plan for tapering analgesia. Also consider whether the patient has had an adequate trial of other treatments. Sample size The number of eligible patients will vary according to your practice demographic. If you identify a large number of patients, take a random sample of 30 patients whose notes you will audit. Data analysis Use the data sheet to record your data and calculate percentages. Identifying opportunities for Audit of Medical Practice The first step to improving medical practice is to identify the criteria where gaps exist between expected and actual performance and then to decide how to change practice. Once a set of priorities for change have been decided on, an action plan should be developed to implement any changes. Taking action It may be useful to consider the following points when developing a plan for action (RNZCGP 2002). Problem solving process What is the problem or underlying problem(s)? Change it to an aim What are the solutions or options? What are the barriers? How can you overcome them? Overcoming barriers to promote change Identifying barriers can provide a basis for change What is achievable find out what the external pressures on the practice are and discuss ways of dealing with them in the practice setting Identify the barriers Develop a priority list Choose one or two achievable goals Effective interventions No single strategy or intervention is more effective than another, and sometimes a variety of methods are needed to bring about lasting change Interventions should be directed at existing barriers or problems, knowledge, skills and attitudes, as well as performance and behaviour Clinical Audit Appropriate prescribing of oxycodone for non-cancer pain 3

Review Monitoring change and progress It is important to review the action plan developed previously at regular intervals. It may be helpful to review the following questions: Is the process working? Are the goals for improvement being achieved? Are the goals still appropriate? Do you need to develop new tools to achieve the goals you have set? Following the completion of the first cycle, it is recommended that the doctor completes the first part of the Audit of Medical Practice summary sheet (Appendix 1). Undertaking a second cycle In addition to regular reviews of progress with the practice team, a second audit cycle should be completed in order to quantify progress on closing the gaps in performance. It is recommended that the second cycle be completed within 12 months of completing the first cycle. The second cycle should begin at the data collection stage. Following the completion of the second cycle it is recommended that practices complete the remainder of the Audit of Medical Practice summary sheet. Claiming MOPS credits This audit has been endorsed by the RNZCGP as an Audit of Medical Practice activity (previously known as Continuous Quality Improvement CQI) for allocation of MOPS credits; 10 credits for a first cycle and 10 credits for a second cycle. General practitioners taking part in this audit can claim credits in accordance with the current MOPS programme. To claim points go to the RNZCGP website: www. rnzcgp.org.nz Record your completion of the audit on the MOPS Online credit summary, under the Audit of Medical Practice section. From the drop down menu, select the audit from the list or select Approved practice/ PHO audit and record the audit name in Notes, the audit date and 10 credits. General practitioners are encouraged to discuss the outcomes of the audit with their peer group or practice. As the RNZCGP frequently audit claims you should retain the following documentation, in order to provide adequate evidence of participation in this audit: 1. A summary of the data collected 2. An Audit of Medical Practice (CQI) Activity summary sheet (included as Appendix 1). Te Whare Tohu Rata o Aotearoa Endorsed CPD Activity bpac nz 10 George Street PO Box 6032, Dunedin phone 03 477 5418 free fax 0800 bpac nz bpac nz better medicin e www.bpac.org.nz/audits

Data sheet cycle 1 Appropriate prescribing of oxycodone for non-cancer pain in general practice Patients prescribed Moderate to severe pain Intolerant or allergic to Plan in place to taper oxycodone morphine analgesia Patient YES/NO YES/NO YES/NO 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 Total Yes % Yes Please retain this sheet for your records to provide evidence of participation in this audit.

Data sheet cycle 2 Appropriate prescribing of oxycodone for non-cancer pain in general practice Patients prescribed Moderate to severe pain Intolerant or allergic to Plan in place to taper oxycodone morphine analgesia Patient YES/NO YES/NO YES/NO 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 Total Yes % Yes Please retain this sheet for your records to provide evidence of participation in this audit.

APPENDIX 1 SUMMARY SHEET Audit of medical practice (CQI activity) Topic: Date: Appropriate prescribing of oxycodone for non-cancer pain in general practice Activity designed by (name of organisation, if relevant): Bpac nz Doctor s name: Results discussed with peer group or colleagues? Date: Yes No FIRST CYCLE DATA: Date of data collection: CHECK: Describe any areas targeted for improvement as a result of analysing the data collected. (If the findings have any implications for health equity, please include this.) ACTION: Describe how these improvements will be implemented. MONITOR: Describe how well the process is working. When will you undertake a second cycle? AUGUST 2016 1

SECOND CYCLE DATA: Date of data collection: CHECK: Describe any areas targeted for improvement as a result of analysing the data collected. (If the findings have any implications for health equity, please include this.) ACTION: Describe how these improvements will be implemented. MONITOR: Describe how well the process is working. COMMENTS: AUGUST 2016 PO Box 10440, The Terrace, Wellington 6134, New Zealand T +64 4 496 5999 F +64 4 496 5997 E rnzcgp@rnzcgp.org.nz W www.rnzcgp.org.nz